PMDA drug package insert
ピコスルファートナトリウム顆粒1％「ゼリア」
PMDA Prescription drug · 日新製薬株式会社 · package insert Dec 13, 2023
Key facts
| Brand names | ピコスルファートナトリウム顆粒1％「ゼリア」 |
|---|---|
| Nonproprietary names | ピコスルファートナトリウム水和物 |
| Companies | 製造販売元／日新製薬株式会社, 販売元／ゼリア新薬工業株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 便通促進・便秘治療剤 |
| Therapeutic category codes | 872359 |
| YJ codes | 2359005D1128 |
| Approval numbers | 30200AMX00548000 |
| Package insert edition | 第1版 |
| Package insert date | Dec 13, 2023 |
| PMDA document key | 530113_2359005D1128_1 |
| PMDA company code | 530113 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: